Oramed Pharmaceuticals (ORMP) Given “Buy” Rating at B. Riley
Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating reissued by B. Riley in a research note issued to investors on Monday, MarketBeat.com reports. They currently have a $20.00 price target on the biotechnology company’s stock. B. Riley’s price objective indicates a potential upside of 134.19% from the stock’s current price.
Several other equities research analysts have also commented on ORMP. ValuEngine upgraded shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a research note on Thursday, October 5th.
Oramed Pharmaceuticals (ORMP) traded down $0.28 during trading hours on Monday, reaching $8.54. 51,900 shares of the company’s stock traded hands, compared to its average volume of 43,298. Oramed Pharmaceuticals has a 52-week low of $5.82 and a 52-week high of $11.34.
WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/11/b-riley-analysts-give-oramed-pharmaceuticals-ormp-a-20-00-price-target.html.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.